Celldex Therapeutics Inc - CLDX STOCK NEWS

Celldex Therapeutics (NASDAQ:CLDX) has announced its management's participation in two upcoming investor conferences. The company will engage in fireside chats at the following events:

• 2024 Cantor Global Healthcare Conference on Tuesday, September 17th at 8:35 a.m. ET
• TD Cowen's Chronic Urticaria Summit on Friday, September 20th at 10:00 a.m. ET

Live webcasts of these presentations will be accessible on the 'Events & Presentations' page of the 'Investors & Media' section on Celldex's website. Replays will remain available for 90 days after each event, providing investors with extended access to the company's insights and updates.

Celldex Therapeutics (NASDAQ:CLDX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

- Initiation of Phase 3 CSU studies in July 2024

- Positive topline Phase 2 CIndU 12-week data reported in July 2024

- Ongoing enrollment in Phase 2 PN and EOE studies

- Planned initiation of Phase 2 AD study by year-end 2024

- CDX-622, first bispecific for inflammatory diseases, to enter clinic this year

Financial results:

- Cash position: $802.3 million as of June 30, 2024

- Q2 2024 revenue: $2.5 million

- Q2 2024 net loss: $35.8 million ($0.54 per share)

Celldex believes its current cash position is sufficient to fund operations through 2027.

Celldex Therapeutics (NASDAQ:CLDX) announced positive topline results from their Phase 2 clinical trial of barzolvolimab in chronic inducible urticaria (CIndU). The study met its primary endpoint, demonstrating a statistically significant difference in the percentage of patients with a negative provocation test compared to placebo at Week 12. Barzolvolimab showed rapid, durable, and clinically meaningful responses in patients with CIndU refractory to antihistamines.

Key findings include:

• 46.9% and 53.1% complete response rates for cold urticaria at 150mg q4w and 300mg q8w doses, respectively
• 57.6% and 42.4% complete response rates for symptomatic dermographism at 150mg q4w and 300mg q8w doses, respectively
• Favorable safety profile with most adverse events being mild to moderate

Celldex plans to advance barzolvolimab into Phase 3 registration development for CIndU.

Celldex Therapeutics (NASDAQ:CLDX) has launched its global Phase 3 program for barzolvolimab in Chronic Spontaneous Urticaria (CSU) patients. The program includes two trials, EMBARQ-CSU1 and EMBARQ-CSU2, enrolling over 1,800 patients who remain symptomatic despite antihistamine or biologic treatments. Barzolvolimab, a novel monoclonal antibody, targets the root cause of CSU by blocking the KIT receptor, essential for mast cell function. The trials will evaluate two dosing regimens against placebo over 52 weeks, with the primary endpoint assessing reduction in urticaria activity at Week 12. This advancement follows successful Phase 2 results, where barzolvolimab demonstrated rapid, durable, and clinically meaningful responses in moderate to severe CSU patients.

Celldex Therapeutics (NASDAQ: CLDX) announced its participation in the Jefferies Healthcare Conference. The management will engage in a fireside chat on June 6, 2024, at 10:00 am ET. A webcast of the presentation will be available on the Celldex website under the 'Events & Presentations' section. The session will be accessible for replay for 90 days after the event.

Celldex Therapeutics (NASDAQ:CLDX) announced significant improvements in angioedema in patients with chronic spontaneous urticaria (CSU) during a Phase 2 trial of barzolvolimab. Data revealed a rapid onset of relief within 2 weeks, sustained through 12 weeks, across various dose groups. The study included 208 participants and demonstrated clinically meaningful and statistically significant advancements in AAS7 scores, with improvements seen in patients regardless of their prior omalizumab status. The 300 mg cohort showed the highest efficacy, with a 25.32 LS mean difference from placebo. The findings, presented at the EAACI Congress 2024, suggest barzolvolimab could become an effective treatment for CSU, leading to the initiation of Phase 3 studies this summer.

Celldex Therapeutics announced the dosing of the first patient in its Phase 2 study of barzolvolimab for treating prurigo nodularis (PN). This humanized monoclonal antibody targets the KIT receptor tyrosine kinase, important for mast cell function, believed to drive chronic itch and neuroinflammation in PN. Earlier Phase 1b results showed significant clinical benefits with barzolvolimab, prompting this larger, double-blind, placebo-controlled study. The trial will assess the efficacy and safety of two dosing regimens in about 120 patients over 40 weeks, aiming to evaluate itch improvement and lesion healing. The study involves 50 global centers, including the U.S.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported Q1 2024 financial results and a corporate update. Phase 3 CSU studies to start in summer 2024. Positive Phase 2 CSU 12-week data presented at AAAAI 2024, with 52-week data to follow later. Phase 2 CIndU study enrollment completed, with Phase 2 PN study ongoing. Atopic dermatitis selected for Phase 2 study by YE 2024. Cash position at $823.8 million. Total revenue at $0.2 million. R&D expenses at $31.7 million. G&A expenses at $9.1 million. Net loss at $32.8 million.